Tag: GlobeNewswire

ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health. The Accountable Care Organization (ACO) will care for more than 36,000 attributed lives in the Medicare Shared Savings Program (MSSP) starting January 1, 2027.

Privia Health paid approximately $36 million at closing using cash on its balance sheet. The transaction is expected to have minimal impact on all key metrics in 2026 and will positively contribute to Attributed Lives and Adjusted EBITDA in 2027.

This strategic transaction further scales Privia Care Partners, adding attributed lives in both existing and new states, and also offers a compelling synergy opportunity for providers to join Privia’s Medical Groups for a full suite of services and technology platform.

“Adding ACH to our national network of ACOs underscores Privia Health’s ability to replicate our differentiated and flexible operating model with new practice partners across the country,” said Sam Starbuck, Senior Vice President and President, Privia Care Partners. “We look forward to collaborating with these physicians and their practices, leveraging our population health and value-based care expertise to enhance the patient experience, improve outcomes, and lower costs.”

About Privia Health

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 6.1+ million patients, and reward 5,600+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

Safe Harbor Statement

This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full-year guidance for 2026. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.

Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the execution of our growth strategy, which may not prove viable and we may not realize expected results; difficulties timely implementing our proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in our industry; challenges in successfully establishing a presence in new geographic markets; the impact of failures by or service disruptions at key third-party vendors, such as our primary electronic medical record vendor, athenahealth, Inc.; potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting our patient population; the financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential security threats, cybersecurity incidents or privacy or other forms of data breaches involving us, our vendors or other third parties; the continued availability of qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Contact
Robert Borchert
SVP, Investor & Corporate Communications
IR@priviahealth.com
817.783.4841

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.

Presentation details are as follows:

Date & Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET)
Session Type: Poster
Session Title: MRI & Imaging

Poster Number: P077
Title: Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies
Presenter: Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular Imaging Research at Austin Health

Poster Number: P082
Title: Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer’s disease spectrum
Presenter: Gerard Nisal Bischof, PD, Director Medical Imaging at Lantheus

About Lantheus 
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Galloway Capital Partners, LLC announced that Galloway Capital, LP and its affiliates, Schedule 13D filers in PodcastOne, Inc. (NASDAQ: PODC), strongly support the Company’s decision to form a Special Committee of the Board of Directors to retain a financial advisor to evaluate strategic alternatives to maximize shareholder value.

Galloway believes PodcastOne’s public market valuation substantially understates the value of its content portfolio, advertising relationships and distribution capabilities, particularly to a strategic acquirer. The Company was recently ranked 6th among participating U.S. podcast publishers and networks measured by Podtrac, reaching approximately 5.8 million unique U.S. listeners.

“PodcastOne has expanded its revenue, programming and audience, yet we believe those achievements remain inadequately reflected in its share price,” said Bruce Galloway, Chief Executive Officer of Galloway Capital Partners. Based on our estimated annual revenue of $68 million to $75 million, applying an illustrative valuation range of 3 to 4x revenue implies an enterprise value of approximately $195 million to $300 million, or approximately $7.00 to $10 per share.   Recent transactions in the sector have been valued at 3 to 13x revenue.

About Galloway Capital Partners, LLC

Galloway Capital Partners, LLC is an investment firm focused on identifying undervalued public companies and engaging constructively to enhance shareholder value.

Contact:
Bruce Galloway
Chief Executive Officer
Galloway Capital Partners, LLC
bgalloway@gallowaycap.com

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding potential value creation and strategic opportunities. Actual results may differ materially from those expressed or implied. Galloway undertakes no obligation to update these statements except as required by law.

Information regarding Galloway Capital Partners and certain matters referenced herein is contained in a Schedule 13D filed with the U.S. Securities and Exchange Commission on October 27, 2026, which is available at www.sec.gov.

Important Disclosures

Revenue estimates and valuation ranges reflect Galloway’s opinions and assumptions, are not Company guidance or an acquisition offer, and do not establish an available transaction price. Forward-looking statements involve risks and uncertainties; actual results may differ materially. No strategic review or transaction is assured. Galloway undertakes no obligation to update these statements except as required by law.

Vancouver, BC, Nov. 02, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, reports that its portfolio company Formic Technologies, Inc. (“Formic”), in which Humanoid Global holds a minority equity interest, has announced that it has raised US$50 million in growth capital (the “Financing”). According to Formic, the Financing comprises a Series B equity round led by Mercato Partners (“Mercato”), with participation from Light Ray Ventures, Lightscape Partners, Citi and other new and existing investors, together with debt financing from S2G Investments.

Formic, which describes itself as the commercialization platform for physical AI, delivers robotic automation to U.S. manufacturers through a Robots-as-a-Service model that bundles equipment, deployment software, field operations, maintenance, financing and performance monitoring into a single recurring monthly payment, with no upfront capital required from the customer. According to Formic, proceeds from the Financing will be used to accelerate its expansion from task-specific automation into general-purpose robotics, strengthen its AI and robotics capabilities, and expand into new applications such as metal fabrication, while deepening its presence in aerospace, space, defense, medical, energy and the broader U.S. industrial base.

According to Formic, it has operated robots in live production for more than five years and now runs hundreds of robots across more than 100 facilities in over 30 states, having accumulated more than 750,000 hours of live production. Formic reports fleet uptime of 99.6% and a customer renewal rate of 97%, with applications spanning palletizing, case packing, machine tending, kitting and assist work across food and beverage, consumer packaged goods, chemicals, aerospace, defense and packaging. Formic also reports that it now deploys robots into production approximately three times faster than it did a year ago, as data from each deployment informs subsequent installations.

Formic has stated that, as part of its move into general-purpose robotics, it is working with Physical Intelligence to adapt Physical Intelligence’s robotic foundation models for manufacturing applications using Formic’s production data and operational expertise. Formic assembles and tests its robots at its facility in Bolingbrook, Illinois, and develops new capabilities at its R&D center in Oakland, California. In connection with the Financing, Ryan Sanders, Managing Director at Mercato, has joined Formic’s Board of Directors.

Formic’s full announcement is available at businesswire.com.

Commenting on the Financing, Saman Farid, founder and CEO of Formic, noted that the gap between building a capable robot and making it productive on a real factory floor remains the industry’s central challenge, and that Formic is now extending its platform “from task-specific automation to general-purpose robotics.” He added that the model allows manufacturers to grow domestic output without committing significant capital to automation.

“Formic’s Series B is an encouraging validation of our investment thesis and of the value we believe exists in the deployment layer of physical AI,” said Sunny Ray, CEO of Humanoid Global. “A syndicate that includes Mercato Partners and Citi is backing a business with a meaningful operating record: hundreds of robots in live production, 99.6% uptime and a 97% renewal rate. As Formic extends its platform into general-purpose and humanoid robotics, we believe it has the potential to become an important channel through which embodied AI reaches American factory floors, and we are pleased that this progress is reflected in the value of our position.”

Humanoid Global previously announced a strategic investment in Formic as part of its mandate to support platforms that accelerate the adoption of autonomous robotics in manufacturing. The Company continues to view Formic as a core holding within its portfolio and consistent with its long-term thesis that commercialization and deployment infrastructure will be important to supporting widescale adoption of humanoid robotics, service robotics and orchestration technologies across key industrial markets.

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp.  (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more:
https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer

finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, but is not limited to, statements regarding: Formic’s intended use of proceeds from the Financing; Formic’s expansion into general-purpose robotics and new applications and industries; Formic’s work with Physical Intelligence; and the Company’s expectations regarding its investment in Formic. Forward-looking information is based on certain assumptions made by the Company at the time such information was provided, including that: Formic will deploy the proceeds of the Financing as described; Formic will continue to operate and pursue its business objectives; and market conditions and demand for robotics and automation technology will remain favorable. The Company holds a minority equity interest in Formic and accordingly has a financial interest in Formic’s success; readers should consider this interest when evaluating the forward-looking information contained herein. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information, including but not limited to: the risk that Formic may not achieve its stated business objectives or successfully expand into general-purpose robotics; the illiquid nature of the Company’s investment in a private company and the absence of a public market for Formic’s securities; the early-stage nature of general-purpose and humanoid robotics; the Company’s reliance on the performance of its portfolio companies, including Formic, in which the Company holds a minority equity interest; competition in the robotics and AI sectors; changes in applicable laws or regulations; general business, economic, and market conditions; and other risks described in the Company’s public filings available on SEDAR+ at www.sedarplus.ca. All forward-looking information in this news release is qualified in its entirety by this cautionary statement and speaks only as of the date hereof. The Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information in this news release regarding Formic, the Financing, Formic’s operating metrics and its business plans has been derived from publicly available sources, including Formic’s news release dated October 22, 2026 and publicly available news coverage. The Company has not independently verified such information.

Amended offer includes 100% of outstanding pre-funded warrants and adds stapled warrants at $0.17 per warrant

Pre-funded warrant holders who tendered before the amendment must tender again

Offer extended to November 12, 2026

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”) today announced amendments to its previously announced cash tender offer (the “Offer”), expanding the Offer to include 100% of the Company’s outstanding cash pre-funded warrants and cryptocurrency pre-funded warrants, as well as all outstanding cash stapled warrants and cryptocurrency stapled warrants. The Company has also extended the expiration of the Offer to one minute after 11:59 p.m., New York City time, on November 12, 2026, unless further extended or earlier terminated.

As previously announced, on October 27, 2026, Bastion Trading Limited and certain of its affiliates (together, “Bastion Trading”) entered into a tender support and settlement agreement (the “Agreement”) with the Company. Under the Agreement, Bastion Trading has agreed to tender all of its shares of common stock, pre-funded warrants and stapled warrants.

“By expanding the tender offer, we are providing all holders of our pre-funded warrants and stapled warrants with an equal opportunity for liquidity on the same terms,” said Paul Danner, Executive Chairman of SkyAI. “These amendments serve the interests of our security holders and allow management to remain focused on building our agentic AI financial platform.”

The Offer will expire at one minute after 11:59 p.m., New York City time, on November 12, 2026, unless further extended or earlier terminated. The Company reminds shareholders and warrant holders who wish to tender that brokers and other nominees may set earlier deadlines.

Holders who have not tendered their shares yet should take action by contacting their broker or the Information agent. Holders who tendered their shares before the amendment do not need to take further action. Holders of pre-funded warrants who tendered before the amendment must tender again using the new documents.

Holders who have not received a DocuSign, or who have questions about how to tender, should contact MacKenzie at (800) 322-2885 or (212) 929-5500, or by email at tenderoffer@mackenziepartners.com. The amended Offer to Purchase and the Letters of Transmittal are available at https://www.skyai.co/investors/tender-offer-materials. The Company’s answers to frequently asked questions are available at https://www.skyai.co/investors/tender-offer-faqs. The amended Offer to Purchase is available at https://www.sec.gov/Archives/edgar/data/1737995/000149315226049311/formsctoia.htm.

Terms of the Amended Offer

The Company is offering to purchase, in cash:

• up to 48,311,489 shares of common stock, or 95% of the class, at $3.00 per share;
• up to 5,137,615 cash pre-funded warrants and up to 10,463,001 cryptocurrency pre-funded warrants, or 100% of each class, at $3.00 per warrant less the $0.0001 exercise price;
• up to 41,054,034 cash stapled warrants and up to 22,159,638 cryptocurrency stapled warrants, or 100% of each class, at $0.17 per stapled warrant. The stapled warrants have an exercise price of $9.75 per share and;
• up to 3,955,293 strategic warrants, or 95% of the class, at $3.00 per warrant less the $0.0001 exercise price.

If all securities sought are tendered, the Company will pay approximately $214.3 million. The Company will pay for the securities purchased, and the related fees and expenses, from cash on hand of approximately $223 million. In the weeks leading up to the commencement of the Offer, the Company sold approximately 2 million SOL at an average price net of fees of $107.20 per SOL. The Company no longer holds any SOL and after the Offer is closed the Company will not be repurchasing SOL. The Offer is not subject to a financing condition.

The Company will announce the preliminary results of the Offer, including any expected proration, on the next business day after the Offer expires. The Company will pay for securities accepted in the Offer promptly after the Offer expires.

Subject to applicable law, the Company does not intend to withhold U.S. federal income tax from payments made to Non-U.S. Holders in the Offer. Holders are urged to consult their own tax advisors about the tax consequences of the Offer. See Section 14 of the Offer to Purchase.

How to Tender

Shares held through a broker. Holders whose shares are held by a broker, dealer, commercial bank, trust company or other nominee should contact that nominee and instruct it to tender. The nominee may set a deadline earlier than the expiration of the Offer, so holders should contact their nominee as soon as possible.

Shares registered with VStock. Holders whose shares are registered in their own name with VStock Transfer, LLC (“VStock”), the Company’s transfer agent, can tender by signing the first DocuSign sent by MacKenzie Partners, Inc. (“MacKenzie”), the Company’s Depositary and Information Agent, titled “SkyAI, Inc. – Tender Offer for Up to 95% of Outstanding Common Stock and Pre-Funded Warrants at $3.00 Each”. They can instead complete the physical Letter of Transmittal mailed to their registered address and send it to MacKenzie at 7 Penn Plaza, Suite 503, New York, NY 10001.

Pre-funded warrants. All pre-funded warrants are held with VStock. Holders can tender them by signing the second DocuSign which will be sent by MacKenzie later today, or by completing the new physical Letter of Transmittal mailed to their registered address. Tenders of pre-funded warrants made before the amendment, through the first DocuSign or the original Letter of Transmittal, are no longer valid. Holders who tendered pre-funded warrants before the amendment must tender them again with the second DocuSign or the new Letter of Transmittal.

Stapled warrants. All stapled warrants are held with VStock and none are held through a broker. Holders can tender them with the same second DocuSign or the new physical Letter of Transmittal.

Holders who already tendered shares. A tender of common stock made before the amendment, through a broker, the first DocuSign or the original Letter of Transmittal, stays in place under the amended Offer. These holders do not need to sign again or give their broker new instructions.

Warrant holders do not need to exercise their warrants before they tender. Holders of pre-funded warrants and strategic warrants will receive $2.9999 per warrant, the amount they would receive by exercising and tendering the underlying share. Holders may withdraw tendered securities at any time before the Offer expires.

No Recommendation Regarding Participation in the Offer

The Board of Directors of the Company (the “Board”) has approved the Offer and the amendments. However, neither SkyAI, the Board, the Company’s directors or officers, nor the depositary and information agent makes any recommendation to any shareholder or warrant holder as to whether the shareholder or warrant holder should tender or refrain from tendering shares or warrants in the Offer or as to the number of shares or warrants a shareholder or warrant holder should tender.

Each shareholder and warrant holder must make his, her or its own decision regarding whether to participate in the Offer and, if so, how many shares or warrants to tender. Shareholders and warrant holders are urged to carefully review the Offer Materials (as defined below) and to consult their own financial, tax and legal advisors in making that decision.

Additional Information Regarding the Offer

This communication is not an offer to buy nor a solicitation of an offer to sell any securities of the Company. The solicitation and offer to buy shares, cash pre-funded warrants, cryptocurrency pre-funded warrants, strategic warrants, cash stapled warrants and cryptocurrency stapled warrants are being made solely pursuant to the Offer to Purchase, the related Letters of Transmittal and the other tender offer materials, as amended (the “Offer Materials”), that the Company has filed as part of a tender offer statement on Schedule TO with the SEC, as amended. Investors may obtain a free copy of these materials and all other documents filed by the Company with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by the Company under the “Investors” section of the Company’s website at www.skyai.co. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS, INCLUDING THE OFFER MATERIALS OF THE COMPANY AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE OFFER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES, CASH PRE-FUNDED WARRANTS, CRYPTOCURRENCY PRE-FUNDED WARRANTS, STRATEGIC WARRANTS, CASH STAPLED WARRANTS AND CRYPTOCURRENCY STAPLED WARRANTS INTO THE OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. THE OFFER MATERIALS CAN ALSO BE FOUND ON THE COMPANY’S WEBSITE AT https://www.skyai.co/investors/tender-offer-materials.

Questions and requests for assistance, or for additional copies of the Offer Materials, may be directed to MacKenzie Partners, Inc. at (800) 322-2885 or (212) 929-5500, or by email at tenderoffer@mackenziepartners.com.

About SkyAI

SkyAI, Inc. (Nasdaq: SKYA) is an artificial intelligence company building an agentic finance platform for the Global South. For additional information, please visit www.skyai.co.

Forward-Looking Statements

This press release contains “forward-looking statements”. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Offer, including its timing, terms, funding and completion, the Company’s strategy and product roadmap and the potential opportunities such initiatives may create. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

Risks and uncertainties that could cause results to differ from expectations include: (i) uncertainties as to the timing and terms of the Offer; (ii) the risk that the Offer may not be completed in a timely manner or at all; (iii) uncertainties as to the percentage of the Company’s shareholders and/or warrant holders tendering their shares or warrants in the Offer; (iv) the possibility that any or all of the various conditions to the consummation of the Offer, including the minimum condition for each class, may not be satisfied or waived; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Offer; (vi) the effect of the announcement or pendency of the Offer on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its operating results and business generally or the trading market for its common stock; (vii) risks related to the Offer diverting management’s attention from the Company’s ongoing business operations; (viii) the risk that shareholder litigation in connection with the Offer may result in significant costs of defense, indemnification and liability; (ix) the Company’s ability to achieve the benefits contemplated by the Offer; and (x) risks and uncertainties pertaining to the Company’s business and the risks and uncertainties detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, as well as the Offer Materials to be filed by the Company in connection with the Offer.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

Depositary and Information Agent
MacKenzie Partners, Inc.
(800) 322-2885 or (212) 929-5500
tenderoffer@mackenziepartners.com

New Fluke ii1050 and ii1030 acoustic imagers combine advanced detection, thermal imaging support, and on-device reporting to quickly uncover issues and reduce unplanned downtime

Everett, Washington, Nov. 02, 2026 (GLOBE NEWSWIRE) — The costliest threats to productivity and profitability are often the ones maintenance teams can’t see. Hidden compressed air leaks waste energy around the clock, while developing electrical and mechanical issues can escalate into safety incidents, equipment failures and unplanned downtime. As industrial organizations face rising energy costs, growing reliability expectations and ongoing workforce shortages, identifying these issues quickly has become more critical than ever.

Organizations need technologies that can uncover hidden issues faster, simplify inspections and enable more confident maintenance decisions. To meet that need, Fluke today introduced the Fluke ii1050 and ii1030 Acoustic Imagers, a new generation of imaging designed to deliver greater acoustic performance in a significantly smaller, lighter platform while simplifying the path from detection to action.

Approximately 40% smaller than previous-generation models and weighing just 1.2 kilograms, the ii1050 and ii1030 make long inspections more comfortable and confined or hard-to-reach areas easier to access. Despite the significantly smaller form factor, the imagers retain the same-size display, now with an anti-glare screen for improved visibility, while an IP54-rated design provides greater protection for demanding industrial environments.

Equipped with 202 microphones, up from 64 in previous-generation models, the cameras can detect fainter sounds and pinpoint their source with greater precision. A high-resolution 13-megapixel camera provides clear visual context, while on-device reporting and an integrated flashlight help teams inspect, diagnose, and document issues in the field. Support for the new TC03A plug-in thermal camera adds thermal imaging to the inspection workflow, giving technicians additional visual context when investigating equipment conditions.

“Maintenance is increasingly less about responding to failures reactively and more about preventing them,” said Tako Feron, Senior Product Manager, Acoustic Imaging, at Fluke. “More complex work means experienced technicians are increasingly scarce, so teams need technologies that turn complex data into clear, insights in the field. The Fluke ii1050 and ii1030 reveal issues that might otherwise go undetected and present information in a way that is intuitive and relevant to the user, enabling faster, more confident decisions on the job. This also supports sustainability by reducing energy waste, improving asset reliability and reducing costly disruptions.”

The ii1050 and ii1030 enable maintenance teams to quickly locate compressed air, gas and vacuum leaks, detect electrical partial discharge, and identify developing mechanical issues from a safe distance. By transforming sound into clear visual insights, the cameras accelerate troubleshooting, support more confident maintenance decisions and help organizations improve reliability while reducing energy waste.

The Fluke ii1050 and ii1030 give maintenance teams the tools to:

• Find compressed air and gas leaks earlier to reduce energy waste and operating costs.
• Detect partial discharge from a safe distance to identify electrical issues before they escalate.
• Identify developing mechanical issues before they lead to equipment failure and costly unplanned downtime
• Inspect more assets in less time with enhanced acoustic performance and a smaller, lighter design.
• Turn findings into action faster with on-device tools to assess, prioritize and report inspection results.

The ii1050 and ii1030 combine leak detection, partial-discharge inspection and mechanical anomaly detection in a single platform, enabling maintenance teams to move from inspection to action faster while supporting reliability, safety and energy-efficiency initiatives.

To learn more about the new Acoustic Imagers, please visit the ii1050 and ii1030 product pages at Fluke.com.

About Fluke
Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measurement and condition monitoring. Fluke customers include technicians, engineers, electricians, maintenance managers and metrologists who install, troubleshoot and maintain industrial, electrical and electronic equipment and calibration processes.

FLUKE is a registered trademark of Fluke Corporation. For more information, visit www.fluke.com.

Media Contacts:

Dave Smith
Fluke Corporation
dave.smith@fluke.com

Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

Q: How do the ii1050 and ii1030 help organizations improve reliability and reduce energy waste?
A: The ii1050 and ii1030 help organizations identify issues that often go unnoticed until they become costly problems. By revealing hidden air and gas leaks, detecting partial discharge activity and identifying developing mechanical issues early, maintenance teams can prioritize corrective action, reduce energy losses, improve asset reliability and avoid unplanned downtime.

Q: How do the ii1050 and ii1030 help maintenance teams do more with fewer resources?
A: The ii1050 and ii1030 combine advanced acoustic imaging, thermal imaging support and on-device reporting in a smaller, lighter design that simplifies inspections and accelerates decision-making. By helping users find issues faster, inspect more assets in less time and document results directly in the field, the cameras improve technician productivity while reducing workflow complexity.

Q: How do the Fluke ii1050 and ii1030 differ from other Fluke acoustic imagers?
A: The ii1050 and ii1030 are Fluke’s most capable acoustic imagers to date, combining enhanced acoustic performance, expanded diagnostic capabilities and streamlined reporting in a significantly smaller, lighter design. Compared to previous-generation models, they feature a 202-microphone array, up from 64 microphones, improving the ability to detect and pinpoint smaller, fainter and more closely spaced sound sources. The cameras also introduce on-device reporting, thermal imaging support, an integrated flashlight, enhanced LeakQ™ and PDQ™ algorithms, expanded storage capacity and improved environmental protection, helping maintenance teams inspect more assets, make faster decisions and document findings more efficiently.

Attachments

• Fluke Unveils Its Most Powerful Acoustic Imagers in a Smaller, Lighter Design
• Fluke Unveils Its Most Powerful Acoustic Imagers in a Smaller, Lighter Design

CONTACT: Dave Smith
Fluke Corporation
dave.smith@fluke.com

LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EST on Thursday, November 12, 2026 to discuss financial results for the quarter ended September 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Phase 3 clinical development of IMNN-001 in newly diagnosed advanced ovarian cancer.

To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.

An audio replay of the call will be available for 90 days and can be accessed at (800) 770-2030 (U.S. and Canada/Toll Free) or (609) 800-9909 (U.S./Toll) using replay access code 4174261#.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The lead modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in an ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

Grand opening ceremony brings together OEM representatives, business partners, and local officials to mark the next chapter of Micware’s North American operations

KOBE, Japan, Nov. 02, 2026 (GLOBE NEWSWIRE) — Micware Co., Ltd. (Nasdaq: MWC) (the “Company” or “Micware”), a Japan-based provider of in-vehicle infotainment, navigation, and location-based software for automakers including Honda and Toyota, today announced that its subsidiary, Micware North America, Inc. (“Micware North America”), celebrated the relocation of its Dublin, Ohio office to a new and expanded workspace at 5525 Parkcenter Circle, Suite 100S, Dublin, Ohio 43017, with a grand opening ceremony held on October 30, 2026. The Company believes that the expanded office reflects the continued growth of Micware’s presence in North America and its ongoing commitment to innovation, collaboration, and the customers and partners it serves in the region.

Micware North America’s New Office at 5525 Parkcenter Circle, Suite 100S, Dublin, Ohio 43017

From left: Takashi Harishima, President of Micware North America; Chris Amorose Groomes, Mayor of Dublin, Ohio; Hideaki Tokuhara, Chief Operating Officer of Micware; and Mike Carey, U.S. Representative for Ohio’s 15th District

Celebrating the Next Chapter of Micware North America

The grand opening ceremony held at the Marriott Columbus Northwest in Dublin, Ohio marked a new milestone for Micware North America more than a decade after Micware established its U.S. presence in 2014. Mr. Kenji Narushima, Founder, Chief Executive Officer and Chairman of Micware, joined representatives of automotive original equipment manufacturers (OEMs), officials from the City of Dublin, business partners, and members of the local community to celebrate the occasion. The event included a formal ribbon-cutting ceremony, an office tour, a reception, and a technology showcase, giving guests an opportunity to explore Micware’s expanded U.S. office and meet the Company’s management and team.

Chris Amorose Groomes, Mayor of Dublin, Ohio, speaks during the ceremony.

The event also featured the presentation of the Patriot Award from Employer Support of the Guard and Reserve (“ESGR”), a U.S. Department of Defense program. Mr. Bob Skinner, Chairman of Central Ohio ESGR, presented the award individually to three Micware North America team members: Mr. Takashi Harishima, President; Mr. Jun Nonomura, Chief Operating Officer; and Mr. Tomonao Matsumoto, Senior Software Engineer. The three recipients were nominated by Micware North America employee Mr. Kevin Zhang, who currently serves in the U.S. Army Reserve, in recognition of their support for his military service.

Showcasing Micware’s Software-Defined Vehicle and Spatial Intelligence Technologies

Technology exhibits formed a central part of the event, highlighting Micware’s established automotive software expertise and its applications across mobility and spatial intelligence. Guests explored the Company’s software-defined vehicle (“SDV”) and location-based services (“LBS”) technologies, including micAuto-PF, its in-vehicle infotainment software platform; AI-powered tools supporting software development and testing; Mvcube, a road infrastructure analysis solution; and 3D digital twin technologies powered by DynaPlanet-PF.

Together, the exhibits illustrated Micware’s capabilities across in-vehicle systems, road infrastructure, and 3D digital environments. The showcase also provided an opportunity to engage with OEM representatives and local officials, reinforcing Micware North America’s role as a key base for software development services to Japanese OEMs outside Japan.

Management Commentary

Mr. Kenji Narushima, Founder, Chief Executive Officer, and Chairman of Micware, commented, “When we established Micware North America in 2014, our goal was to be closer to the customers and partners we serve and to build lasting relationships in this market. Over the years, those relationships have become an important part of Micware’s journey. Our U.S. team has continued to grow, and our new office is now twice the size of our previous workspace. Seeing our customers, partners, and members of the local community come together for this opening made this milestone especially meaningful for all of us.”

Mr. Narushima continued, “This new office represents more than a larger workspace. It represents the next chapter of what we hope to build in North America. We intend to continue building our presence here in Dublin, together with our customers, partners, and the local community. We want to continue supporting the customers who have grown with us, while exploring opportunities to introduce more of Micware’s platforms and technologies, including micAuto-PF and DynaPlanet-PF, to the market. I am deeply grateful to everyone who has supported Micware North America over the years, and I look forward to what we can accomplish together from this new home.”

About Micware Co., Ltd.

Micware Co., Ltd. (Nasdaq: MWC) is a Japan-based provider of in-vehicle infotainment, navigation, and location-based software for automakers including Honda and Toyota. These capabilities also form the foundation of its spatial intelligence business.

Headquartered in Kobe and led by Founder and CEO Mr. Kenji Narushima since 2003, Micware operates 13 offices in Japan, with overseas subsidiaries in the United States, Thailand, and Germany.

Through a platform-based growth strategy, Micware aims to extend its software into advanced driver assistance and connected services with micAuto-PF, and to link real-world and virtual 3D spaces with DynaPlanet-PF.

For more information, visit Micware’s IR website at www.ir-micware.com and its LinkedIn page at www.linkedin.com/company/micware-company-limited.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”). Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the annual report on Form 20-F and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

Micware Co., Ltd.
Investor Relations Department
Phone: +81-3-6699-9899
Email: mic_ir@micware.co.jp

Public Relations
Email: mic_pr@micware.co.jp

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/8c60702d-06e7-4ef3-96a2-5dc04a23ae3c 
https://www.globenewswire.com/NewsRoom/AttachmentNg/7e1f6d22-61dc-4238-8874-9f3b6f0f156d

New Findings from Academic Collaboration Examine Tumor-Cell Behavior, TGF-Β/SMAD Signaling & Stromal Responses; Australian Patent Application Filed for the Combination Approach

MELBOURNE, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced highlighted new preclinical findings evaluating its pancreatic proenzyme formulation (PRP) alone and in combination with galunisertib (GAL), a small-molecule inhibitor of transforming growth factor beta receptor I (TGF-βRI), in pancreatic ductal adenocarcinoma (PDAC) models. The Company has filed an Australian patent application relating to the combination approach.

The research was conducted in collaboration with investigators at the University of Jaén and the University of Granada in Spain. The study compared PRP, GAL and PRP plus GAL in wild-type BxPC-3 pancreatic cancer cells, gemcitabine-resistant BxPC-3 cells, normal-associated fibroblasts (NAFs) and cancer-associated fibroblasts (CAFs). Experiments assessed cell proliferation, colony formation, migration and invasion, together with molecular readouts associated with TGF-β signaling, epithelial–mesenchymal transition (EMT), extracellular-matrix (ECM) remodeling and fibroblast activation.

PDAC is characterized by complex interactions between malignant cells and the surrounding tumor microenvironment. TGF-β signaling can contribute to tumor-cell plasticity, EMT and stromal activation, although its effects depend on cellular context. The study investigated whether PRP could modulate these tumor- and stroma-associated processes and whether adding a TGF-β pathway inhibitor provided further effects.

“Our academic collaboration with the Universities of Jaén and Granada in Spain continues to provide strong scientific evidence and a rationale for the administration of PRP as a stand-alone therapy, but also as a combinatorial approach with inhibitor drugs that can successfully stop tumor growth and dissemination but can be limited due to resistance mechanisms developed over time as a result of alterations to the tumor microenvironment,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “PRP represents a new approach addressing these resistance mechanisms by inducing biological effects that alters the behavior of these malignant cells, rather than using the inhibitory approach. Our unique intellectual property portfolio continues to grow and strengthen as a result and is positioning the Company for long-term future growth, which our shareholders understand will come to fruition as future planned R&D milestones are achieved. Management believe these milestones are near term as PRP (now called Company Candidate, PPC-001) enters the clinic. Further announcements are expected regarding current preparatory activities for our Phase 1b, First-In-Human study as we progress further.”

Key preclinical findings:

• Anti-proliferative activity in tumor models: PRP reduced cell proliferation by approximately 50% in wild-type and gemcitabine-resistant BxPC-3 cells relative to untreated controls. PRP plus GAL reduced proliferation by 75% and 66%, respectively. The additional reduction versus PRP alone was significant in wild-type cells; in resistant cells, the further reduction was not statistically significant.
• Reduced long-term colony-forming capacity: PRP reduced colony formation by 59% in wild-type cells and 39% in gemcitabine-resistant cells. The combination reduced colony formation by 68% and 64%, respectively. The additional effect of the combination over PRP alone was significant in the resistant model, but not in the wild-type model.
• Suppression of migration and invasion: In wound-healing assays at 72 hours, wound closure was 21% with PRP in wild-type cells and 57% in resistant cells, compared with untreated controls. PRP plus GAL resulted in 19% and 30% wound closure, respectively; the combination significantly improved the result over PRP alone in resistant cells, but not in wild-type cells. In Matrigel invasion assays, PRP reduced invasion by 81% in wild-type cells and 47% in resistant cells. PRP plus GAL produced reductions of 89% and 80%, respectively.
• Modulation of TGF-β/SMAD pathway-associated gene expression: PRP significantly reduced SMAD2, SMAD3 and TGFBR1 transcript levels to 0.45-, 0.63- and 0.55-fold of control in wild-type cells, and to 0.42-, 0.36- and 0.23-fold in resistant cells, compared to control group. The combination produced further reductions in selected readouts, although the magnitude and statistical significance of the additional effects varied across models and markers.
• Changes in EMT-associated markers: PRP increased E-cadherin expression 5.29-fold in wild-type cells and 4.86-fold in resistant cells, while reducing Vimentin to 0.31- and 0.32-fold and Snail to 0.62- and 0.28-fold, respectively, relative to untreated controls. The combination produced additional changes in selected biomarkers, including stronger suppression of Snail in the resistant-cell model. These transcriptional findings are consistent with a shift towards a more epithelial gene-expression profile; they do not establish complete reversal of EMT.
• Changes in genes are linked to tumor aggressiveness and cell survival: In wild-type cells, PRP reduced MYC and SOX2 expressions to 0.27- and 0.54-fold of control, respectively, and increased the pro-apoptotic marker BAX 2.49-fold. In resistant cells, MYC and SOX2 fell to 0.11- and 0.22-fold, while BAX increased 2.74-fold. These are gene-expression results and can be interpreted as degree of apoptosis.
• Differential responses in fibroblast populations: PRP reduced CAF proliferation by up to 53% and CAF invasion by 85%, while its effect on NAF proliferation was modest and not statistically significant (approximately 22% reduction); NAF invasion was reduced by 19%. The gene-expression data showed a similar differential response. In CAFs, PRP reduced αSMA, FAPα and YAP1 expression to 0.56-, 0.27- and 0.58-fold of untreated-control levels, respectively. It also reduced COL1A1, FN1, MMP9, IL6 and CXCL12 expressions to 0.65-, 0.42-, 0.49-, 0.25- and 0.54-fold of control, respectively. In NAFs, the corresponding reductions in COL1A1, FN1, MMP9, IL6 and CXCL12 expression were not statistically significant (0.81-, 0.86-, 0.76-, 0.75- and 0.81-fold of control, respectively); αSMA expression was 0.81-fold of control, YAP1 was 0.89-fold, and FAPα expression was undetectable. Overall, the pattern suggests a more pronounced effect on activated CAFs than on NAFs.
• Combination effects and stromal selectivity: Compared with PRP monotherapy, the addition of GAL enhanced the inhibition of selected CAF-associated functional and molecular features, although it also increased the impact on normal-associated fibroblasts. In proliferation assays PRP + GAL reduced CAF proliferation by 71%, compared with 53% with PRP alone, while inhibition in NAFs increased from a non-significant 22% with PRP to 55% with the combination. In clonogenic assays, the combination reduced colony formation by 78% in CAFs, compared with 69% with PRP alone; however, it also reduced NAF clonogenic capacity by 42%, whereas PRP largely preserved it. This additional reduction in NAF clonogenicity was significant (38.9% relative to PRP), while the additional reduction in CAFs was not significant (19.5%). Regarding migration, PRP + GAL limited wound closure in CAFs to 28% at 72 hours, compared with 35% with PRP alone, whereas NAF wound closure reached 100% under both treatment conditions. In Matrigel assays, the combination further reduced invasion in CAFs from 85% with PRP alone to 90%, while the reduction in NAF invasion increased from 19% to 32%. At the molecular level, PRP + GAL produced a slightly greater downregulation of CAF-associated genes than PRP alone, reducing COL1A1, FN1, MMP9, IL6 and CXCL12 expression to 0.40-, 0.32-, 0.29-, 0.16- and 0.32-fold of control levels, respectively, compared with 0.65-, 0.42-, 0.49-, 0.25- and 0.54-fold with PRP alone. The combination also reduced CAF activation markers αSMA and FAPα to 0.45- and 0.19-fold of control, respectively, compared with 0.46- and 0.30-fold with PRP. In NAFs, the combination reduced COL1A1, FN1, MMP9, IL6 and CXCL12 expressions to 0.63-, 0.85-, 0.56-, 0.68- and 0.80-fold of control, respectively, indicating broader effects than PRP monotherapy, for which these changes were modest and not statistically significant. Overall, PRP alone showed a more favorable stromal selectivity profile, whereas the addition of GAL enhanced suppression of several CAF-associated markers but also increased effects on NAF proliferation, clonogenicity and invasion.

What the findings mean

The addition of galunisertib enhanced the suppression of several CAF-associated markers, including genes involved in ECM remodeling and inflammatory signaling, and further reduced selected functional endpoints, particularly tumor-cell and CAF invasion. However, these additional effects were not uniform across all assays. Importantly, GAL-containing treatment also increased the suppression of several readouts in NAFs, including proliferation and clonogenic capacity. This distinction raises an important question: whether stronger inhibition of TGF-β associated signaling necessarily produces a more favorable overall response, or whether preserving the selectivity of the stromal response may be equally important. Within the conditions tested, PRP monotherapy showed a more favorable profile in terms of differential effects on CAFs and NAFs, whereas the combination produced broader stromal suppression at the expense of some of this apparent selectivity.

These findings do not establish that preserving NAF function improves clinical outcomes, but they support investigating stromal selectivity as an important parameter when evaluating future combination strategies.

In tumor cells, PRP also demonstrated activity across multiple functional and molecular endpoints in both wild-type and gemcitabine-resistant BxPC-3 models. These effects included reduced proliferation, colony-forming capacity, migration and invasion, together with changes in TGF-β/SMAD-associated signaling and EMT-related gene expression. Increased E-cadherin expression alongside reduced vimentin and Snail expression was consistent with a shift towards a more epithelial transcriptional profile, while changes in MYC, SOX2 and BAX suggested additional effects on genes associated with tumor-cell aggressiveness and apoptotic regulation. The combination with GAL enhanced selected responses, particularly invasion suppression in resistant tumor cells, although the magnitude of the additional benefit varied between models and experimental endpoints. These observations support further investigation of PRP as a potential modulator of aggressive tumor-cell phenotypes, including in a gemcitabine-resistant setting.

A central hypothesis emerging from this study is that PRP may offer a dual advantage: modulating aggressive tumor-cell characteristics while preferentially attenuating features of activated tumor-supportive stroma. TGF-β inhibition may reinforce some of these effects, but its broader impact on normal-associated fibroblasts suggests that the optimal therapeutic strategy may not simply be the one that produces the greatest overall suppression. Instead, the balance between tumor-directed activity, CAF modulation and preservation of normal stromal functions may be critical.

“These preclinical findings provide a rationale for continued investigation of PRP, both as a monotherapy and in combination with TGF-β pathway inhibition, in pancreatic cancer,” said Dr. Maria Belén Toledo, Lead Investigator at the University of Jaén. “They also identify stromal selectivity as a potentially valuable consideration in treatment development and suggest that therapeutic value of targeting the tumor microenvironment should be assessed not only by the extent of pathway suppression, but also by which cellular populations are affected and how this translates into tumor control. Further validation in more complex models will be conducted to confirm whether these effects can be reproduced and support a clinically meaningful therapeutic strategy.”

Illustration of the proposed effects of PRP and TGF-β pathway inhibition on tumor cells and the tumor microenvironment

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6b88acd9-0745-449d-9f68-a061a7553c5d

ATLANTA, GA, Nov. 02, 2026 (GLOBE NEWSWIRE) — Trust Stamp (NASDAQ:IDAI), a global provider of AI-powered software solutions, today announced that CEO Gareth N. Genner will provide a live presentation on the Company’s progress and 2027 business plan from 11:00 to 11:30 ET on November 18, 2026. The presentation will be livecast as a part of the OTC Markets Small Cap Growth Virtual Investor Conference and made available to 1.7 million B2iDigital subscribers. An additional live Q&A session for investors and analysts will be held at 13:00 on the same day.

About Trust Stamp

Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that ensure technology and data sovereignty, reduce fraud, tokenize and secure assets and data, and securely authenticate users while protecting personal privacy, reducing friction in digital transactions, and increasing operational efficiency. With team members from over twenty nationalities in ten countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (NASDAQ:IDAI).

Inquiries: shareholders@truststamp.ai

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks 

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.